Response to comment on Genuth. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on! Diabetes Care 2015;38:170-175.

I appreciate the attention Schrijnders et al. (1) have given to the Counterpoint article on use of sulfonylureas as an addon to metformin (2). Several sulfonylureas were compared with regard to the risk of hypoglycemia, but gliclazide was neglected, as it is unfortunately not available in the U.S. Gliclazide was also not mentioned in the Point article by… CONTINUE READING